Shortness of Breath: Drugs That Cause or Treat It

What Is Dyspnea and Why Do Drugs Matter?

Shortness of breath, clinically called dyspnea, is a subjective sensation of difficult or uncomfortable breathing that ranges from mild chest tightness to air hunger. It represents one of the most common reasons for emergency department visits in the United States, accounting for approximately 3.5 million ED presentations annually according to CDC National Hospital Ambulatory Medical Care Survey data [1]. Medications are an underappreciated cause.

Drug-induced dyspnea is frequently overlooked because clinicians default to cardiac and pulmonary explanations first. A 2020 review in the BMJ noted that medication side effects account for a significant minority of unexplained dyspnea cases in primary care, particularly among patients on polypharmacy regimens with five or more concurrent drugs [2]. The relationship between drugs and breathing difficulty is bidirectional: some medications directly impair respiratory mechanics or gas exchange, while others treat the underlying conditions that produce breathlessness. Understanding both directions is essential for any patient experiencing new or worsening dyspnea.

The American Thoracic Society defines dyspnea as "a subjective experience of breathing discomfort that consists of qualitatively distinct sensations that vary in intensity" [3]. This definition matters because patients on culprit medications may describe their symptoms differently from those with primary lung disease. A patient on a beta-blocker might report "chest tightness" rather than "can't catch my breath," leading clinicians away from the medication as a cause.

Drugs That Commonly Cause Shortness of Breath

Several drug classes are well-documented triggers of dyspnea, ranging from mild exercise intolerance to life-threatening pulmonary toxicity. Recognizing these patterns can prevent months of unnecessary testing.

Beta-blockers are among the most frequent pharmacologic causes of breathing difficulty. Non-selective agents like propranolol and nadolol block beta-2 receptors in bronchial smooth muscle, producing bronchoconstriction. A meta-analysis published in The Lancet found that cardioselective beta-blockers (metoprolol, bisoprolol, atenolol) produced a clinically insignificant 7.5% mean reduction in FEV1 in COPD patients, while non-selective agents produced meaningful airflow obstruction [4]. The effect is dose-dependent. Patients with underlying asthma face the highest risk, with the FDA labeling for propranolol carrying a specific contraindication for bronchospastic disease [5].

ACE inhibitors cause cough in 5-35% of patients, a side effect mediated by bradykinin accumulation in the airways [6]. This persistent dry cough can produce a sensation indistinguishable from dyspnea, particularly during exertion. The NEJM review on ACE inhibitor cough noted that the cough typically begins within the first few months of treatment and resolves within 1-4 weeks of discontinuation [7]. Switching to an ARB eliminates the cough in approximately 95% of affected patients.

NSAIDs can trigger bronchospasm in aspirin-exacerbated respiratory disease (AERD), affecting roughly 7% of adult asthmatics. Ibuprofen, naproxen, and aspirin inhibit cyclooxygenase-1, shunting arachidonic acid toward leukotriene synthesis. The resulting bronchoconstriction can be severe. NIH guidelines recommend that all patients with nasal polyps and asthma be evaluated for AERD before receiving NSAIDs [8].

Amiodarone produces pulmonary toxicity in 5-7% of patients receiving long-term therapy. The presentation ranges from acute respiratory distress to slowly progressive interstitial fibrosis. A study in the Annals of Internal Medicine reported that amiodarone pulmonary toxicity carries a mortality rate of 10-23% when diagnosed late [9]. Baseline and annual pulmonary function tests are recommended for all patients on this drug, per AHA guidelines [10].

Methotrexate causes hypersensitivity pneumonitis in 0.3-11.6% of patients, according to a Cochrane review [11]. The reaction is not dose-dependent and can occur at any point during treatment. Symptoms include acute dyspnea, non-productive cough, and fever. The ACR guidelines recommend baseline chest radiography and pulmonary function testing before starting methotrexate for rheumatoid arthritis [12].

Other notable offenders include bleomycin (dose-dependent pulmonary fibrosis affecting up to 46% of patients receiving cumulative doses above 400 units), nitrofurantoin (both acute and chronic pulmonary reactions), and certain biologics like checkpoint inhibitors, which produce immune-mediated pneumonitis in 3-5% of treated patients [13].

Drugs That Treat Shortness of Breath

The pharmacologic approach to treating dyspnea depends entirely on its underlying cause. No single drug treats "shortness of breath" generically, but several classes address the most common etiologies.

Short-acting beta-agonists (SABAs) like albuterol remain the first-line rescue treatment for acute bronchospasm. Albuterol relaxes bronchial smooth muscle within 5-15 minutes by stimulating beta-2 adrenergic receptors, with effects lasting 4-6 hours. The GINA 2024 guidelines recommend against SABA-only treatment for asthma, instead pairing it with an inhaled corticosteroid as reliever therapy to reduce exacerbation risk [14]. This was a significant shift in management.

Long-acting bronchodilators form the maintenance backbone of COPD treatment. The UPLIFT trial (N=5,993) demonstrated that tiotropium (a long-acting muscarinic antagonist) improved FEV1 by 87-103 mL over placebo at 4 years, with significant reductions in exacerbations and dyspnea scores [15]. Combination LABA/LAMA inhalers (umeclidinium/vilanterol, tiotropium/olodaterol) provide additive bronchodilation. The EMAX trial (N=2,431) showed umeclidinium/vilanterol produced clinically meaningful improvements in Transition Dyspnea Index scores versus either component alone, published in the Annals of the American Thoracic Society [16].

Inhaled corticosteroids (ICS) reduce airway inflammation and exacerbation frequency in both asthma and eosinophilic COPD. The TORCH trial (N=6,112) showed salmeterol/fluticasone combination reduced moderate-to-severe COPD exacerbations by 25% compared to placebo, with parallel improvements in health status and dyspnea, as reported in the NEJM [17].

Loop diuretics are the primary treatment for dyspnea caused by pulmonary congestion in heart failure. Intravenous furosemide produces symptomatic relief within 30-60 minutes by reducing preload and pulmonary capillary wedge pressure. The DOSE trial (N=308) compared low-dose versus high-dose furosemide strategies in acute decompensated heart failure and found that higher doses produced greater fluid loss and dyspnea relief, with no significant difference in renal outcomes at 72 hours [18]. The study was published in the NEJM [19].

Opioids and Palliative Approaches to Refractory Dyspnea

For patients with persistent breathlessness despite optimal disease-directed therapy, low-dose opioids represent the most evidence-based pharmacologic intervention. This is not about pain. It is about modulating the brain's perception of respiratory effort.

A Cochrane systematic review of 26 studies (N=526 participants) found that systemic opioids significantly reduced the sensation of breathlessness compared to placebo, with oral or parenteral administration preferred over nebulized delivery [20]. Dr. David Currow, a palliative care researcher, has stated: "Low-dose morphine for breathlessness has a stronger evidence base than many treatments we use routinely in medicine." The typical starting dose is 2-5 mg of oral morphine every 4 hours, titrated to effect [21].

The American Thoracic Society's 2024 clinical practice guideline on dyspnea management endorses opioids for refractory breathlessness, noting that "the fear of respiratory depression at these low doses is not supported by the evidence" [22]. Respiratory depression requires doses 5-10 times higher than those used for dyspnea palliation. Benzodiazepines, by contrast, lack consistent evidence for dyspnea relief and carry sedation risks. The same ATS guideline recommends against routine benzodiazepine use for dyspnea unless anxiety is a dominant co-occurring symptom [22].

Pulmonary rehabilitation, while not a drug, produces dyspnea reductions equivalent to or greater than most pharmacologic interventions. The Cochrane review of pulmonary rehabilitation (N=3,822 across 65 trials) showed clinically significant improvements in dyspnea and quality of life in COPD, with benefits persisting up to 12 months [23].

Cardiac Medications and Breathing: The HFpEF Connection

Heart failure with preserved ejection fraction (HFpEF) accounts for roughly half of all heart failure cases, and exertional dyspnea is its hallmark symptom. Until recently, no drug had demonstrated clear benefit for HFpEF-related breathlessness. That changed.

The EMPEROR-Preserved trial (N=5,988) showed empagliflozin (an SGLT2 inhibitor) reduced the composite of cardiovascular death or heart failure hospitalization by 21% in HFpEF patients (HR 0.79 to 95% CI 0.69-0.90), as published in the NEJM [24]. Dyspnea-specific outcomes improved significantly in the treatment group. The FDA subsequently approved empagliflozin for heart failure regardless of ejection fraction [25].

SGLT2 inhibitors work through osmotic diuresis and natriuresis, reducing plasma volume and pulmonary congestion without the neurohormonal activation that accompanies loop diuretics. Dapagliflozin showed similar benefits in the DELIVER trial (N=6,263), with consistent effects across the ejection fraction spectrum [26].

GLP-1 receptor agonists have emerged as another drug class with potential breathing benefits. The STEP-HFpEF trial (N=529) demonstrated that semaglutide 2.4 mg weekly produced significant improvements in Kansas City Cardiomyopathy Questionnaire scores (including the dyspnea domain) and 6-minute walk distance in obese HFpEF patients, published in the NEJM [27]. Mean body weight loss was 13.3% with semaglutide versus 2.6% with placebo at 52 weeks. These improvements in dyspnea appear to be mediated by both weight loss and direct anti-inflammatory effects on the myocardium and vasculature.

How to Identify Drug-Induced Dyspnea

Recognizing medication-related breathlessness requires a systematic temporal approach. The onset of dyspnea relative to drug initiation or dose change is the single most valuable diagnostic clue.

A practical framework for clinicians and patients includes four steps. First, establish timing: did symptoms begin within days to weeks of starting a new medication or increasing a dose? Second, check the drug's known adverse-effect profile using the FDA Adverse Event Reporting System (FAERS) database [28]. Third, perform a dechallenge: if clinically safe, discontinue or reduce the suspected agent and observe for improvement over 1-4 weeks. Fourth, consider rechallenge only if the risk-benefit calculation favors restarting the drug and no safer alternative exists.

Pulmonary function testing (spirometry with bronchodilator response) can differentiate obstructive drug effects (beta-blockers, NSAIDs) from restrictive patterns (amiodarone, methotrexate, bleomycin). High-resolution CT of the chest is indicated when drug-induced interstitial lung disease is suspected. Bronchoalveolar lavage may be necessary to exclude infection in immunosuppressed patients before attributing pneumonitis to a medication.

The Naranjo Adverse Drug Reaction Probability Scale provides a validated 10-question scoring system that quantifies the likelihood of a drug causing an adverse effect [29]. A score of 9 or higher indicates a definite adverse drug reaction; 5-8 indicates probable. This tool is underused in clinical practice for respiratory complaints.

When Shortness of Breath Requires Emergency Evaluation

Not all dyspnea can be managed with medication adjustments. Certain presentations demand immediate medical attention regardless of suspected drug etiology.

Call 911 or go to the nearest emergency department for sudden-onset breathlessness at rest, dyspnea accompanied by chest pain or pressure, cyanosis (blue discoloration of lips or fingertips), inability to speak in full sentences due to breathlessness, or new dyspnea with leg swelling and a history of recent immobility (suggesting pulmonary embolism). The AHA guidelines emphasize that acute dyspnea with hemodynamic instability requires emergent evaluation for pulmonary embolism, tension pneumothorax, acute coronary syndrome, and cardiac tamponade [30].

Subacute presentations, those developing over days to weeks, warrant urgent outpatient evaluation. These include progressive exercise intolerance, orthopnea (needing to sit up to breathe), paroxysmal nocturnal dyspnea (waking from sleep with breathlessness), and new wheezing in a patient without known asthma or COPD. Chest X-ray, BNP or NT-proBNP, complete blood count, and basic metabolic panel form the minimum initial workup [31].

D-dimer testing using age-adjusted cutoffs (age x 10 mcg/L for patients over 50) combined with Wells criteria can safely exclude pulmonary embolism in low-to-moderate probability patients, avoiding unnecessary CT pulmonary angiography. The ADJUST-PE trial (N=3,346) validated this approach, finding that age-adjusted D-dimer cutoffs increased specificity from 34.4% to 46.0% without missing clinically significant PE [32].

Medications in Development for Dyspnea

Several investigational compounds target dyspnea through novel mechanisms. Ensifentrine, a dual PDE3/PDE4 inhibitor, received FDA approval in 2024 as the first new inhaled mechanism for COPD maintenance in over a decade [33]. It combines bronchodilator and anti-inflammatory effects in a single molecule. The ENHANCE trials (ENHANCE-1 and ENHANCE-2, combined N=1,615) demonstrated significant improvements in FEV1 trough values and reductions in COPD exacerbations compared to placebo [34].

Dupilumab, an IL-4/IL-13 inhibitor already approved for asthma with type 2 inflammation, is being studied in COPD with eosinophilic phenotype. The BOREAS trial (N=939) showed dupilumab reduced moderate-to-severe COPD exacerbations by 30% (rate ratio 0.70 to 95% CI 0.58-0.86) in patients with blood eosinophils of 300 cells per microliter or higher, published in the NEJM [35]. Dyspnea scores improved significantly by week 12 and the benefit was sustained through week 52.

Patients experiencing unexplained shortness of breath should bring a complete medication list, including over-the-counter drugs, supplements, and recent changes, to every medical appointment. Start with the medication timeline: the drug you added last is the one most likely to be causing new symptoms [28].